RxDoctor Payments DataLook up a doctor →

Richard Rachima, MD

Family Medicine · Charlotte, NCNPI 1659344398

Payments from drug & device makers

$293,990in general payments, 2019–2025

Across 3,111 payments — averaging $94.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$69K
  • Bayer$54K
  • Amarin Pharma, Inc.$29K
  • AstraZeneca$26K
  • Supernus Pharmaceuticals, Inc.$24K
  • Pfizer$22K
  • plus $70K from 54 others

What the payments were for

  • Consulting fees$1,0020%
  • Speaking & faculty fees$237,65081%
  • Travel & lodging$8,7593%
  • Food & beverage$46,49316%
  • Education$860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)451$69,152
Bayer184$54,208
Amarin Pharma, Inc.69$28,748
AstraZeneca159$25,776
Supernus Pharmaceuticals, Inc.109$23,609
Pfizer148$21,677
Esperion Therapeutics, Inc.148$17,672
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC308$10,052
Biohaven Pharmaceuticals, Inc.27$9,400
Cequr Corporation4$7,091
Biohaven Pharmaceutical Holding Company Ltd.16$2,136
Lilly USA, LLC132$1,983
Novo Nordisk149$1,902
Amgen(2 entities)100$1,767
Kowa Pharmaceuticals America, Inc.166$1,523
GSK97$1,440
Otsuka America Pharmaceutical, Inc.82$1,310
Antares Pharma, Inc.60$1,166
Novartis17$1,091
Aytu Biopharma, Inc.58$958
Johnson & Johnson48$869
Boehringer Ingelheim49$862
Exact Sciences20$740
Sumitomo Pharma America, Inc.33$676
Paratek Pharmaceuticals, Inc.39$665
Takeda Pharmaceuticals U.S.A., Inc.39$553
Neos Therapeutics, LP37$521
Sanofi-aventis U.S. LLC23$513
Merck39$460
Halozyme Inc15$418
Axsome Therapeutics, Inc.22$382
Xeris Pharmaceuticals, Inc.20$304
Phathom Pharmaceuticals, Inc.12$289
Astellas Pharma US Inc17$280
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)13$223
Bausch Health US, LLC20$210
Medtronic5$207
Abbott5$201
Arbor Pharmaceuticals, Inc.13$199
Daiichi Sankyo Inc.11$196
Idorsia Pharmaceuticals US Inc11$195
Optinose US, Inc.6$192
Eisai Inc.14$175
Teva Pharmaceuticals USA, Inc.12$159
Almatica Pharma LLC4$138
Vivus LLC8$135
Hikma Pharmaceuticals USA7$114
Alkermes, Inc.5$105
Tolmar, Inc.6$93
Verity Pharmaceuticals Inc.4$86
Corcept Therapeutics6$86
Adlon Therapeutics L.p.5$84
Genentech USA, Inc.5$82
Medicure Pharma Inc.2$82
Avanir Pharmaceuticals, Inc.5$81
E.r. Squibb & Sons, L.L.C.5$81
Insulet Corporation3$62
Sunovion Pharmaceuticals Inc.3$58
Ironwood Pharmaceuticals, Inc3$57
Lundbeck LLC3$55

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$293,990 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$114,660
Medicare patients
196
Services billed
3,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide125$130,451
MounjaroTirzepatide84$111,727
KerendiaFinerenone137$107,149
VascepaIcosapent Ethyl180$106,143
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$91,423
NexlizetBempedoic Acid/Ezetimibe143$89,653
FarxigaDapagliflozin Propanediol55$65,239
EliquisApixaban81$59,387
RybelsusSemaglutide52$56,948
TrulancePlecanatide60$50,750
VraylarCariprazine Hcl32$48,862
JardianceEmpagliflozin51$41,671
LinzessLinaclotide63$39,962
GemtesaVibegron62$39,595
XareltoRivaroxaban45$34,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,902$187,399177 claims
Lilly USA, LLCMounjaro, Trulicity$1,983$133,43496 claims
BayerKerendia$54,208$107,149137 claims
GSKTrelegy Ellipta$1,440$91,423107 claims
Esperion Therapeutics, Inc.Nexlizet$17,672$89,653143 claims
AbbVieVraylar, Linzess$69,152$88,82495 claims
PfizerEliquis, Nurtec Odt$21,677$80,15295 claims
AstraZenecaFarxiga, Breztri Aerosphere$25,776$79,77680 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Relistor$10,052$79,09374 claims
Boehringer IngelheimJardiance, Synjardy Xr$862$70,37688 claims
Johnson & JohnsonXarelto, Invokana$869$41,70058 claims
Sumitomo Pharma America, Inc.Gemtesa$676$39,59562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →